These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30034594)

  • 1. Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-
    Calandro P; Iovenitti G; Zamperini C; Candita F; Dreassi E; Chiariello M; Angelucci A; Schenone S; Botta M; Mancini A
    ACS Med Chem Lett; 2018 Jul; 9(7):646-651. PubMed ID: 30034594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
    Talarico C; D'Antona L; Scumaci D; Barone A; Gigliotti F; Fiumara CV; Dattilo V; Gallo E; Visca P; Ortuso F; Abbruzzese C; Botta L; Schenone S; Cuda G; Alcaro S; Bianco C; Lavia P; Paggi MG; Perrotti N; Amato R
    Oncotarget; 2015 Nov; 6(35):37511-25. PubMed ID: 26462020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Biological Characterization of the Pyrazolo[3,4-
    Contadini C; Cirotti C; Carbone A; Norouzi M; Cianciusi A; Crespan E; Perini C; Maga G; Barilà D; Musumeci F; Schenone S
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery.
    Vignaroli G; Calandro P; Zamperini C; Coniglio F; Iovenitti G; Tavanti M; Colecchia D; Dreassi E; Valoti M; Schenone S; Chiariello M; Botta M
    Sci Rep; 2016 Feb; 6():21509. PubMed ID: 26898318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolo pyrimidine-type inhibitors of SRC family tyrosine kinases promote ovarian steroid-induced differentiation of human endometrial stromal cells in vitro.
    Maruyama T; Yamamoto Y; Shimizu A; Masuda H; Sakai N; Sakurai R; Asada H; Yoshimura Y
    Biol Reprod; 2004 Jan; 70(1):214-21. PubMed ID: 14522827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
    Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold.
    Ortuso F; Amato R; Artese A; D'antona L; Costa G; Talarico C; Gigliotti F; Bianco C; Trapasso F; Schenone S; Musumeci F; Botta L; Perrotti N; Alcaro S
    J Chem Inf Model; 2014 Jul; 54(7):1828-32. PubMed ID: 24896223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
    Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Cytotoxicity, Antimicrobial and Docking Simulation of Novel Pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[3,4-c] pyrimidine Derivatives.
    Hassaneen HM; Saleh FM; Abdallah TA; Mohamed MF; Mohamed YS; Awad EM; Abdelhamid IA
    Mini Rev Med Chem; 2019; 19(8):657-670. PubMed ID: 30332953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.
    Lv H; Zhang Z; Wu X; Wang Y; Li C; Gong W; Gui L; Wang X
    PLoS One; 2016; 11(1):e0145195. PubMed ID: 26727592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.
    Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR
    Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: Preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line.
    Fallacara AL; Mancini A; Zamperini C; Dreassi E; Marianelli S; Chiariello M; Pozzi G; Santoro F; Botta M; Schenone S
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3196-3200. PubMed ID: 28558969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system.
    Azam MA; Dharanya L; Mehta CC; Sachdeva S
    Acta Pharm; 2013 Mar; 63(1):19-30. PubMed ID: 23482310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.